# Wall Street's Wild Stock Rollercoaster: October Edition Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-10-24T14:00:00.177Z Source: https://newsyai.com/edition/4d70558c-acfd-44d4-acaa-8ab7f6ee08fb Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 24, 2026 Edition**[[1]](https://tapeboard.com/most-shorted-stocks)[[2]](https://www.chartmill.com/stock/markets/usa/screener/most-shorted-stocks) Back at it, you beautiful degenerates. Markets are still the same glorious shitshow—AI hype juicing the Nasdaq while the Dow sits on its ass like a retiree in Boca, and crude oil bounces around like a drunk on a pogo stick. I scoured the freshest short-interest scans (recent settlement data with live borrow fees and volatility overlays) for three *brand-new* names where the bears are piled higher than a Wall Street bonus pool on a bad year, and the bulls are yelling “squeeze me harder.” No repeats of the usual suspects like WULF, NVAX, ASTS, ONDS, BBAI, EOSE, SOUN, or the rest of the graveyard. Just pure, unfiltered fresh meat with serious short pressure and “prove me wrong, bitch” vibes. Here’s today’s unholy trinity. ### 1. PRME (Prime Medicine): The Gene-Editing Upstart That’s Either Rewriting DNA for Profit or Just Another Biotech Burning Cash on Prime-Time Fantasies **The Bull Case (Differentiated Prime Editing Tech with Early Wins, Partnerships, and Squeeze Potential):** Bulls are creaming over PRME’s prime editing platform—supposedly more precise than standard CRISPR, with early clinical data, a BMS partnership, and near-term catalysts like liver program readouts in 2027. Any positive trial beats, regulatory nods, or deal expansions could spark a short squeeze (short interest ~28% of float in recent reads, with volatility adding fuel). “We’ve got the better scissors—watch the edits flow and shorts get PRME-d” is the battle cry. Platform potential? Margin inflection from royalties? Shorts left editing their regrets.[[3]](https://www.financecharts.com/stocks/PRME/bulls-bears)[[4]](https://www.tipranks.com/news/the-fly/oppenheimer-bullish-on-prime-medicine-initiates-with-an-outperform-thefly-news) **The Bear Case (Cash-Burning Spec with Dilution Risks, Execution Hurdles, and Crowded Gene-Editing Space):** Reality check: Pre-revenue or minimal, massive cash burn, ongoing losses, dilution via equity raises to fund trials, intense competition from bigger CRISPR players, and questions about whether prime editing delivers superior safety/efficacy in humans. High shorts reflect the market’s “yeah, right” on turning platform hype into approved drugs and recurring revenue without blowing up the balance sheet. One missed readout, funding crunch, or safety signal and it’s dilution or worse. Prime Medicine? More like “prime-time for shorts to harvest the downside.”[[5]](https://gainseekers.com/stocks/prime-medicine-inc-prme-stock-analysis-forecast/)[[6]](https://www.marketbeat.com/instant-alerts/price-prime-medicine-nasdaq-prme-stock-price-down-81-heres-why-2026-10-23/) **My First-Principles Breakdown:** Strip it down: Gene editing wins on precision, delivery, durability, safety margins, and scalable manufacturing—not just cool tech or early partnerships. PRME has a differentiated approach and some validation, but “dominance” requires surviving clinical/funding cycles, proving real-world superiority over incumbents, and hitting commercial scale without excessive dilution. Shorts correctly flag the binary risks and runway concerns; bulls correctly flag the asymmetric upside if the platform delivers. High-vol biotech bet—entertaining as hell, size accordingly or cry into your empty pipette later. ### 2. IREN (Iris Energy): The Bitcoin Miner That’s Either Powering the AI Data Center Boom or Just Hashing Its Way Through Crypto Volatility and Debt **The Bull Case (Efficient Mining + AI/HPC Pivot with Scale Potential and Squeeze Fuel):** Bulls drool over IREN’s low-cost power assets, Bitcoin mining efficiency, and shift toward AI/HPC data center hosting—think contracted revenue potential amid AI demand. Any production beats, AI lease wins, or Bitcoin rallies could trigger a short squeeze (short interest ~21-23% of float recently, with volatility screaming opportunity). “We’ve got the juice and the rigs—watch the MW flow and shorts get IREN-ized” is the hype. Crypto tailwinds? Margin expansion? Shorts left mining regrets.[[7]](https://curvedtrading.com/stocks/iren/short-interest/)[[8]](https://www.benzinga.com/trading-ideas/movers/26/10/62530944/why-is-iren-stock-falling-on-thursday-3) **The Bear Case (High-Vol Crypto Beta Drowning in Capex, Dilution, and AI Execution Risks):** Reality bites: Ongoing losses, heavy capex needs for expansion, Bitcoin price swings still dominate, competition in both mining and data centers, dilution threats from equity raises, and skepticism on timely AI pivots delivering stable revenue. High shorts reflect the market’s “yeah, right” on hitting sustainable profitability without blowing up the balance sheet. One crypto winter, funding crunch, or missed AI deal and it’s dilution or worse. Iris Energy? More like “iris the downside—shorts are harvesting the hash rate.”[[8]](https://www.benzinga.com/trading-ideas/movers/26/10/62530944/why-is-iren-stock-falling-on-thursday-3) **My First-Principles Breakdown:** Fundamentally, energy infrastructure wins on cheap/reliable power, operational efficiency, contract stickiness, and capital discipline—not just shiny miners or hype pivots. IREN has real assets and momentum, but “breakout” requires surviving crypto cycles, proving AI economics beat pure miners or hyperscalers, and scaling without excessive dilution. Shorts correctly price in the volatility and leverage risks; bulls correctly price in the asymmetric upside if AI demand explodes. High-vol crypto/AI bet—entertaining as hell, size accordingly or cry into your empty rig later. ### 3. NTLA (Intellia Therapeutics): The CRISPR Player That’s Either Delivering One-and-Done Gene Edits or Just Another Biotech with Safety Red Flags and Dilution Drama **The Bull Case (Late-Stage Pipeline Momentum with HAE/ATTR Wins and Squeeze Potential):** Bulls are fired up on NTLA’s CRISPR platform progress—strong Phase 3 data in hereditary angioedema (HAE), ATTR programs advancing post-hold, partnerships, and potential first approvals/launch. Any regulatory wins, data beats, or commercial prep updates could spark a short squeeze (short interest ~33% in recent scans, with volatility adding fuel). “We’ve got the edits and the data—watch the approvals flow and shorts get NTLA-minated” is the mantra. Platform validation? Revenue inflection? Shorts left editing regrets.[[9]](https://seekingalpha.com/article/4922003-intellia-therapeutics-an-overvalued-biotech-with-little-to-no-commercial-potential)[[10]](https://businessquant.com/stocks/ntla/) **The Bear Case (Safety Concerns, Crowded Competition, Cash Burn, and Commercial Uncertainty):** Reality check: Clinical holds or safety signals (liver events), heavy cash burn and dilution needs, competition from established therapies and other gene editors, questions on real-world adoption for one-time edits vs. chronic treatments, and valuation assuming flawless execution on launches. High shorts reflect the market’s “yeah, right” on turning promising data into profitable products without setbacks. One more safety issue, regulatory snag, or slow uptake and it’s dilution or worse. Intellia? More like “no-tellia the value—shorts are editing the downside.”[[9]](https://seekingalpha.com/article/4922003-intellia-therapeutics-an-overvalued-biotech-with-little-to-no-commercial-potential)[[11]](https://seekingalpha.com/article/4880086-intellia-therapeutics-stock-why-clinical-hold-lift-not-total-victory) **My First-Principles Breakdown:** CRISPR/gene editing wins on safety, efficacy durability, delivery precision, manufacturability, and payer adoption—not just early data or platform hype. NTLA has meaningful clinical progress and de-risking events, but “success” requires surviving regulatory/safety cycles, proving superior outcomes vs. incumbents, and achieving commercial scale without burning runway. Shorts correctly flag the risks and competition; bulls correctly flag the asymmetric upside if launches deliver. High-vol biotech bet—entertaining as hell, size accordingly or cry into your empty Cas9 later. **Bottom Line (No Crystal Ball, Just Brutal Logic):** These three capture the current divided vibe: prime editing binary, Bitcoin-to-AI energy pivot lottery, and CRISPR launch gamble. The common thread? Sky-high skepticism via shorts and volatility, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don’t), and remember: this is entertainment with numbers. Your move, degenerates. **Sources for the terminally curious (verify this shit yourself):** Recent short-interest trackers and screens (e.g., Tapeboard, ChartMill, MarketBeat, Seeking Alpha) highlighting elevated levels in PRME, IREN, and NTLA; analyst commentary and company filings on sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don’t cry when it goes tits up.